

3. Babjuk M, Burger M, Capoun O, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). *Eur Urol.* 2022 Jan; 81(1): 75–94. doi: 10.1016/j.eururo.2021.08.010. Epub 2021 Sep 10. PMID: 34511303.
4. Schwaibold HE, Sivalingam S, May F, Hartung R. The value of a second transurethral resection for T1 bladder cancer. *BJU Int.* 2006 Jun; 97(6): 1199–201. doi: 10.1111/j.1464-410X.2006.06144.x. Epub 2006 Mar 23. PMID: 16566814.
5. Cumberbatch MGK, Foerster B, Catto JWF, et al. Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review. *Eur Urol.* 2018 Jun; 73(6): 925–933.
6. Lin L, Guo X, Ma Y, et al. Does repeat transurethral resection of bladder tumor influence the diagnosis and prognosis of T1 bladder cancer? A systematic review and meta-analysis. *Eur J Surg Oncol.* 2023 Jan; 49(1): 29–38. doi: 10.1016/j.ejso.2022.06.005. Epub 2022 Jun 13. PMID: 35752497.
7. Blindheim AJ, Fosså SD, Babigumira R, Andreassen BK. The use of reTURB in T1 bladder cancer: a Norwegian population-based study. *Scand J Urol.* 2021 Aug; 55(4): 268–274.
8. Soria F, D'Andrea D, Moschini M, et al. Predictive factors of the absence of residual disease at repeated transurethral resection of the bladder. Is there a possibility to avoid it in well-selected patients? *Urol Oncol.* 2020 Mar; 38(3): 77.e1–77.e7.
9. Dalbagni G, Vora K, Kaag M, et al. Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer. *Eur Urol.* 2009 Dec; 56(6): 903–10. doi: 10.1016/j.eururo.2009.07.005. Epub 2009 Jul 17.